Crinetics Pharmaceuticals

Yahoo Finance • 18 days ago

Crinetics Pharmaceuticals Solicita Autorização de Comercialização de Palsonify™ (Paltusotina) no Brasil para Tratamento de Acromegalia

SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- A Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) anunciou hoje que deu entrada em um Pedido de Autorização de Comercialização (MAA) à Agência Nacional de Vigilância Sanitária (ANVISA) do Bras... Full story

Yahoo Finance • 18 days ago

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil’s National Health Surveillance Agency (ANVISA) for PALSO... Full story

Yahoo Finance • last month

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough

On February 17, 2026, Driehaus Capital Management disclosed a buy of Xenon Pharmaceuticals(NASDAQ:XENE), adding 369,577 shares in an estimated $15.52 million trade based on quarterly average pricing. What happened According to an SEC fil... Full story

Yahoo Finance • last month

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know

Driehaus Capital Management disclosed a significant buy of Eos Energy Enterprises(NASDAQ:EOSE) in its February 17, 2026, SEC filing, adding 7.70 million shares in an estimated $110.72 million trade based on quarterly average pricing. What... Full story

Yahoo Finance • 2 months ago

Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight

The dynamics of the acromegaly market are anticipated to change due to extensive R&D, the entry of novel therapies such as Debio 4126 (Debiopharm International SA), ALXN2420 (AstraZeneca), MAR002 (Marea Therapeutics), Paltusotine (Crinetic... Full story

Yahoo Finance • 4 months ago

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan... Full story

Yahoo Finance • 4 months ago

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate atumelnant, a novel, onc... Full story

Yahoo Finance • 4 months ago

Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Piper Sandler reiterated that Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the stocks to own... Full story

Yahoo Finance • 4 months ago

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somat... Full story

Yahoo Finance • 5 months ago

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSW... Full story

Yahoo Finance • 5 months ago

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purc... Full story

Yahoo Finance • 5 months ago

Crinetics Pharmaceuticals Inc Q3 Loss Increases, Misses Estimates

(RTTNews) - Crinetics Pharmaceuticals Inc (CRNX) reported Loss for its third quarter that increased from the same period last year and missed the Street estimates. The company's earnings came in at -$130.09 million, or -$1.38 per share.... Full story

Yahoo Finance • 6 months ago

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purch... Full story

Yahoo Finance • 6 months ago

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company managemen... Full story

Yahoo Finance • 7 months ago

Stocks Finish Higher as Core PCE Prices Match Expectations

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) on Friday closed up +0.59%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/f... Full story

Yahoo Finance • 7 months ago

Notable Friday Option Activity: TDOC, CRNX, WYNN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Teladoc Health Inc (Symbol: TDOC), where a total of 35,521 contracts have traded so far, representing approximately 3.6 million un... Full story

Yahoo Finance • 7 months ago

Stocks Climb on Strength in Consumer Spending and Tame Inflation

The S&P 500 Index ($SPX) (SPY) today is up +0.56%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.81%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.28%.  December E-mini S&P futures (ESZ25) are up +0.53%, and December E-mini Nas... Full story

Yahoo Finance • 7 months ago

Stocks Turn Mixed as US Consumer Sentiment Slips

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.10%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • 7 months ago

Crinetics wins FDA approval for acromegaly therapy

[US Food and Drug Administration (FDA)] Crinetics Pharmaceuticals (NASDAQ:CRNX [https://seekingalpha.com/symbol/CRNX]) has received approval for its lead asset, Palsonify (paltusotine), as a first-line treatment for adults with acromegaly... Full story

Yahoo Finance • 7 months ago

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where PALSONIFY was well tolerate... Full story